<DOC>
	<DOCNO>NCT02994342</DOCNO>
	<brief_summary>Evaluation ZP-025 vaginal gel term efficacy safety treatment vaginal dryness post-menopausal woman vaginal atrophy comparison group non-treated post-menopausal woman vaginal atrophy 56 consecutive day 4-week follow-up woman apply ZP-025 vaginal gel .</brief_summary>
	<brief_title>Efficacy Tolerability Study ZP-025 Vaginal Gel Treatment Vaginal Dryness</brief_title>
	<detailed_description>Evaluation ZP-025 vaginal gel term efficacy , tolerability safety treatment vaginal dryness post-menopausal woman vaginal atrophy comparison group non-treated post-menopausal woman vaginal atrophy 56 consecutive day . This trial conduct compliance last version Declaration Helsinki , GCP applicable investigation IMD , applicable regulatory requirement CRO Sponsor 's SOPs . This multi-centre , national , randomize , control vs. no-treatment , open label study The study take place 6 center menopause public Hospitals/Universities . An ancillary study carry subject randomize ZP-025 group follow-up visit 4 week</detailed_description>
	<criteria>caucasian woman &lt; 70 year , physiological postmenopausal status least 2 year ; woman sign symptom vaginal atrophy ( i. e. vaginal discomfort , itching , dyspareunia , dryness ) ; sign informed consent ; willing able comply study procedure childbearing potential woman ; ascertain presumptive hypersensitivity formulation ingredient ; therapy systemic vaginal oestrogen within 6 month inclusion ; current urinary vaginal infection ( cultural positive result vaginal urine microbiological swab 7 day precede inclusion ) ; previous episode vaginal bleed spot last 6 month ; vaginal prolapse disease could interfere study conduction participation</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>vaginal dryness</keyword>
	<keyword>vaginal gel</keyword>
	<keyword>colostrum</keyword>
	<keyword>vaginal atrophy</keyword>
</DOC>